Targeting PKCδ as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer

Volume: 34, Issue: 6, Pages: 954 - 969.e4
Published: Dec 1, 2018
Abstract
•PKCδ is a common mediator shared by multiple TKI-resistant pathways•TKI-induced EGFR heterodimers promote nuclear PKCδ and TKI resistance•Nuclear PKCδ associates with worse TKI response in EGFR-mutant NSCLC patients•Inhibition of PKCδ sensitizes resistant EGFR-mutant NSCLC to EGFR TKI Multiple mechanisms of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been identified in EGFR-mutant non-small cell...
Paper Details
Title
Targeting PKCδ as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer
Published Date
Dec 1, 2018
Volume
34
Issue
6
Pages
954 - 969.e4
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.